secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002053
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio launches NIVIS Fibrillar Collagen Pack for surgical wound management
-----------------------------------------------------------------------------

- NIVIS is an absorbent matrix of Type I and Type III bovine collagen for moderately to heavily exudating wounds and minor bleeding.
- The product complements the OviTex portfolio and expands TELA's soft-tissue preservation offerings.
- Commercial launch follows an exclusive development and distribution partnership with Collagen Matrix, Inc. announced in April 2022.
- NIVIS is provided in particulate form to be molded and packed into wounds, facilitating contact with host tissue.
- Product targets general, plastic, and reconstructive surgery markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923002053/0001104659-23-002053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923002053/tm232660d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer